Clinical Trial

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-18.
Trial Details
NCT Number NCT07368270
Lead Sponsor Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Conditions Diffuse Large B Cell Lymphoma
Enrollment 30 participants
Start Date 2026-01
Primary Completion 2027-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28